The highest estimate is 55.00. From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
The current price of VOGX is $20.25 USD — it has increased by +1.66% in the past 24 hours. Watch Vogenx stock price performance more closely on the chart.
What is Vogenx stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Vogenx stocks are traded under the ticker VOGX.
What is Vogenx market cap?▼
Today Vogenx has the market capitalization of 300.82M
When is the next Vogenx earnings date?▼
Vogenx is going to release the next earnings report on December 2, 2026.
What were Vogenx earnings last quarter?▼
VOGX earnings for the last quarter are -0.09 USD per share, whereas the estimation was -0.07 USD resulting in a -21.43% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Vogenx revenue for the last year?▼
Vogenx revenue for the last year amounts to 0 USD.
What is Vogenx net income for the last year?▼
VOGX net income for the last year is -1.45M USD.
How many employees does Vogenx have?▼
As of November 2, 2026, the company has 5 employees.